Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection.

Ther Adv Med Oncol · 2018 · PMC6024333 · PMID 29977349

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an observed trendno p-value reported

77 Interestingly, in those patients in whom an initial response to treatment with atezolizumab compared with sunitinib was demonstrated, there was an observed trend towards a prolonged PFS (12.6 versus 8.3 months) if subsequently treated with the combination of atezolizumab and bevacizumab on progression.

also in 504 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.